0000000000174603
AUTHOR
C. Loustalot
showing 4 related works from this author
Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients.
2020
Abstract With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing. Over 4 years, 2500 patients with an indication for genetic testing underwent a gene cancer panel. If an IF was detected, patients were contacted by a physician/genetic counsellor and invited to take part in a semi-structured interview to assess their understanding of the result, the change in medical care, the psychological impact, and the transmission of results to the f…
Quel impact de l’ACOSOG sur une cohorte multicentrique française de patientes avec ganglion sentinelle positif ?
2013
L’essai americain ACOSOG Z-0011 a remis en cause l’interet du curage axillaire (CA) en cas d’envahissement limite des ganglions sentinelles (GS) chez les patientes presentant un cancer du sein apres traitement conservateur [1]. En Europe, ce nouveau standard est loin d’etre accepte par tous et de fait, de nombreuses questions demeurent. Quelle proportion de patiente europeenne avec GS+ pourrait beneficier d’une abstention de CA en tenant compte des criteres de l’ACOSOG ? Dans quelle mesure une cohorte selectionnee en Europe selon les criteres ACOSOG differerait de la population rapportee dans l’ACOSOG ? a l’inverse, le pronostic des patientes non eligibles par les criteres de l’ACOSOG est-i…
Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium
1999
This study was aimed at evaluating the in vitro effects of phosphodiesterase inhibitors and beta2-adrenoceptor agonists on spontaneous contractions of human term myometrium. Rolipram, RP 73401 (3-cyclopentyloxy-N-(3,5(-dichloro-4-pyridil)-4-methoxybenzamide) and Ro 20-1724 (1-4-(3-butoxy-4-methoxybenzyl)-2-imidozolidinone) (phosphodiesterase 4 inhibitors) inhibited spontaneous myometrial contractions (Emax approximately 100%; pD2 of 6.80+/-0.28, 6.84+/-0.32 and 6.31+/-0.03, respectively). Salbutamol and formoterol were less effective (Emax=40+/-6% and 35+/-12%, respectively) than phosphodiesterase 4 inhibitors to reduce myometrial contractility. Inhibitors of phosphodiesterase 3 (milrinone …
Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
2010
Abstract The known breast cancer susceptibility polymorphisms in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, and 2q35 confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers. We evaluated the associations of 3 additional single nucleotide polymorphisms (SNPs), rs4973768 in SLC4A7/NEK10, rs6504950 in STXBP4/COX11, and rs10941679 at 5p12, and reanalyzed the previous associations using additional carriers in a sample of 12,525 BRCA1 and 7,409 BRCA2 carriers. Additionally, we investigated potential interactions between SNPs and assessed the implications for risk prediction. The minor alleles of rs4973768 and rs10941679 were associated with increased breast cancer risk for BRCA2 carrie…